Also known as Teribone™ Injection.
Phase III trial will test continued Teribone use beyond the 24‑month limit in severe osteoporosis patients at high risk of fracture.
Domestic Phase III trial to assess extended therapy beyond 24 months for patients with severe osteoporosis at high fracture risk; evaluates efficacy and safety of continued treatment.
MAIA will develop and commercialize Teribone™ in the U.S. to address the growing osteoporosis patient population, expanding access to proven bone-forming therapy.
Sales up 6%, net income up 28%, EPS up 30%. Strong growth in Pharma and Closures. $70M returned to shareholders.
